A Phase I/II study of Azacitidine (Vidaza®) in pediatric patients with relapsed high-grade pediatric MDS or JMML.

Trial Profile

A Phase I/II study of Azacitidine (Vidaza®) in pediatric patients with relapsed high-grade pediatric MDS or JMML.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Jul 2018 Planned number of patients changed from 65 to 24.
    • 28 Jul 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2021.
    • 06 Aug 2017 Planned End Date changed from 1 Jan 2016 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top